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Background and aims: Omega-3 fatty acids are known to have several cardioprotective 2 
effects. Our aim was to investigate the effects of intakes of fish and Camelina sativa oil 3 
(CSO), rich in alpha-linolenic acid, on the atherogenic and anti-atherogenic functions of LDL 4 
and HDL particles.  5 
Methods: Altogether, 88 volunteers with impaired glucose metabolism were randomly 6 
assigned to CSO (10 g of alpha-linolenic acid/day), fatty fish (4 fish meals/week), lean fish (4 7 
fish meals/week) or control group for 12 weeks. 79 subjects completed the study. The binding 8 
of lipoproteins to aortic proteoglycans, LDL aggregation and activation of endothelial cells 9 
by LDL and cholesterol efflux capacity of HDL were determined in vitro.  10 
Results: Intake of CSO decreased the binding of lipoproteins to aortic proteoglycans in a non-11 
normalized model (p=0.006). After normalizing with serum concentrations of non-HDL 12 
cholesterol, apolipoprotein B (apoB) or LDL cholesterol, which decreased in the CSO group, 13 
the change was no longer statistically significant. In the fish groups, there were no changes in 14 
the binding of lipoproteins to proteoglycans. Regarding other lipoprotein functions, there 15 
were no changes in any of the groups. 16 
Conclusions: Intake of CSO decreases the binding of lipoproteins to aortic proteoglycans by 17 
decreasing serum LDL cholesterol concentration, which suggests that the level of apoB-18 
containing lipoproteins in the circulation is the main driver of lipoprotein retention within the 19 
arterial wall. Intake of fish or CSO has no effects on other lipoprotein functions. 20 
 21 
Keywords: cholesterol efflux, diet, human, interleukin-8, LDL aggregation, omega-3 fatty 22 
acid, proteoglycan 23 
24 
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1. Introduction 25 
 26 
Progression of atherosclerosis consists of several molecular and inflammatory processes, 27 
taking place in the arterial wall [1-3]. The initiating process in atherogenesis is retention of 28 
lipoproteins, mainly LDL particles, in the arterial intima. Lipoproteins containing 29 
apolipoprotein B (apoB) and apoE bind to proteoglycans of the intimal layer and can be 30 
modified, e.g. by oxidation and lipolysis. Modified lipoproteins may further aggregate or fuse 31 
[4], which increases their binding strength to proteoglycans [5, 6] and prevents their exit back 32 
to the bloodstream [7]. The aggregation susceptibility of LDL varies among individuals and 33 
was recently shown to associate with cardiovascular deaths [8]. LDL, particularly when 34 
modified, also stimulate several atherogenic processes, such as interleukin-8 (IL-8) secretion 35 
of endothelial cells, which induce the chemotactic recruitment of monocytes to the arterial 36 
intima [1, 9, 10]. Modified lipoproteins are taken up by macrophages, which leads to foam-37 
cell formation. Retained and modified lipoproteins and foam cell formation leads to the 38 
release of proinflammatory cytokines and bridging molecules (e.g. lipoprotein lipase), 39 
smooth muscle cell proliferation, induced synthesis of proteoglycans and eventually further 40 
entrapment of lipoproteins [4, 11]. These reactions trigger a self-accelerating process that 41 
eventually leads to progression of atherosclerosis.   42 
 43 
Cholesterol efflux from macrophage foam cells has a central role in the reverse cholesterol 44 
transport, which is considered the primary anti-atherogenic mechanism of HDL [12]. HDL 45 
particles, however, possess also several other atheroprotective activities, such as anti-46 
inflammatory and antioxidative functions [12, 13]. The profile and structure of HDL particles 47 
are key mediators of their atheroprotective functions. Examples of structural components, 48 
which can mediate HDL function, are apoE and serum amyloid A (SAA) [14, 15]. ApoE is 49 
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known to have several anti-atherogenic functions such as mediating plasma lipoprotein 50 
clearance by the liver [14]. Furthermore, apoE has been shown to contribute to lipid retention 51 
via HDL [16]. HDL particles containing apoE can bind to proteoglycans and, therefore, 52 
interfere with the formation of LDL-proteoglycan complex. This competition of binding sites 53 
could potentially prevent LDL accumulation in the arterial wall. Another component which 54 
could impair the atheroprotective functions of HDL is SAA, which is carried primarily in 55 
HDL particles in plasma [15]. SAA is considered a potential mediator of atherosclerosis by 56 
acting as a bridging protein between lipoproteins and proteoglycans and impairing cholesterol 57 
efflux capacity.  58 
 59 
Diet is an important modifiable lifestyle factor in the prevention of CVD [17, 18]. Among the 60 
beneficial dietary factors, fish has been considered as an important component in a 61 
cardioprotective diet. Fish, especially fatty fish, is a rich source of n-3 polyunsaturated fatty 62 
acids (n-3 PUFAs), which have been shown to affect several molecular mechanisms and 63 
pathways related to CVD, such as physical and chemical properties of cellular membranes, 64 
inflammation and regulation of gene expression [19]. Previous studies have shown that intake 65 
of n-3 PUFAs from fish increases HDL cholesterol level but has no effect on LDL cholesterol 66 
[20] whereas evidence on the effects of plant-derived n-3 fatty acid, alpha-linolenic acid 67 
(ALA), on serum lipids is inconsistent [21]. In addition to fatty fish, also lean fish intake has 68 
been found to have cardioprotective effects [22-24]. This suggests that the beneficial effects 69 
of fish consumption on CVD risk factors may, in addition to n-3 PUFAs, be mediated 70 
through other components in the fish, such as protein and other bioactive compounds or their 71 
interactions.  72 
 73 
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Although the effects of n-3 PUFAs on CVD have been extensively studied, little is known 74 
about the effects of dietary intake of these fatty acids on lipoprotein functions related to 75 
atherosclerosis. To this end, the aim of our study was to investigate the effect of Camelina 76 
sativa oil (CSO), high in ALA, and fish intake on the pro- and anti-atherogenic functions of 77 
LDL and HDL particles, such as binding of lipoproteins to aortic proteoglycans, LDL 78 
aggregation, cholesterol efflux capacity and activation of endothelial cells in subjects with 79 
impaired glucose metabolism. 80 
81 
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2. Materials and methods 82 
 83 
2.1 Subjects 84 
Details of the subjects, study design and recruitment were described previously [25]. Briefly, 85 
volunteers aged 40 to 75 years and with impaired glucose metabolism were recruited from 86 
Kuopio area. Glucose metabolism was one of the primary endpoints in this study and, 87 
therefore, the main inclusion criterion was fasting plasma glucose concentration 5.6–6.9 88 
mmol/l. The 2-h glucose concentration in the oral glucose tolerance test had to be ≤ 11.0 89 
mmol/l. A total of 79 subjects completed the study. Subjects were randomly assigned into 90 
four parallel groups for 12 weeks: CSO, lean fish, fatty fish or control group. Randomization 91 
was stratified by sex and use of statins. The subjects received both oral and written 92 
information and informed consent was obtained from all of the subjects. The study was 93 
approved by the Ethical committee of the Hospital District of Northern Savo (55/2012) and 94 
ethical guidelines were followed throughout the study. 95 
 96 
2.2 Study design 97 
The study diets were isocaloric and current nutrient recommendations [26] were followed 98 
except for fish and ALA intakes. Fish diets included four fish meals per week, e.g. salmon, 99 
Baltic herring and vendace in the fatty fish group providing around 1 g of EPA+DHA per day 100 
and e.g. pike, perch, pike-perch and saithe in the lean fish group. The CSO group ingested 30 101 
ml of CSO (27 g) in order to get 10 g of ALA per day. Intake of ALA > 4.5 g/day has been 102 
shown to result in increased levels of EPA in the plasma phospholipids [27]. The control and 103 
CSO groups were allowed to eat one fish meal per week and were instructed to consume lean 104 
meat and chicken. Subjects kept daily consumption records regarding the intake of fish 105 
(number of meals and type of fish) and subjects in the CSO group recorded also the intake of 106 
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CSO. Food records from four consecutive days, including one weekend day, were collected 107 
and checked at return by clinical nutritionists at baseline and during the study in weeks 3, 7 108 
and 11. In the CSO group, intakes of total fat, PUFA and ALA increased as compared with 109 
the control group. In the fatty fish group, intakes of EPA, DHA and vitamin D increased and 110 
intake of carbohydrates decreased as compared with the control group. In the lean fish group 111 
intake of vitamin D increased as compared with the control group. Detailed dietary intakes 112 
have been reported previously [25].  113 
 114 
The blood samples were drawn after 10-hour overnight fasting at baseline (0 wk) and at the 115 
end of the study (12 wk). Physical activity, alcohol intake, smoking, body weight and use of 116 
medications known to affect the measures of lipid metabolism were to be kept constant 117 
during the study. As an objective measure of compliance, the proportions of plasma fatty 118 
acids in phospholipids were measured using gas chromatography as previously described [28] 119 
with an exception of using C19:0 as an internal standard instead of C17:0. 120 
 121 
2.3 Analytical methods 122 
Binding of lipoproteins to proteoglycans 123 
Proteoglycan binding was assessed in 96-well plates coated with proteoglycans isolated from 124 
human aortas as previously described [29]. 1 µl plasma was added to the wells and incubated 125 
for 1 h. The amount of cholesterol bound to the wells was measured with Amplex Red 126 
cholesterol assay kit. 127 
 128 
 129 
 130 
 131 
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Isolation of LDL and HDL  132 
LDL (d = 1.019–1.063 g/ml) and HDL (d = 1.063–1.210 g/ml) were prepared from isolated 133 
plasma by sequential flotation ultracentrifugation using D2O for density adjustment as 134 
described previously [30]. 135 
 136 
LDL aggregation 137 
LDL was isolated from the plasma and LDL stability was determined by inducing LDL 138 
aggregation by human recombinant sphingomyelinase as previously described [8]. LDL 139 
aggregation was followed by measuring the particle size using dynamic light scattering.  140 
 141 
Culture of human coronary artery endothelial cells (HCAECs) and analysis of LDL effect on 142 
endothelial cell activation 143 
HCAECs (PromoCell) were cultured in Endothelial Cell Growth Medium MV supplemented 144 
with 5% fetal calf serum, 0.4% endothelial cell growth supplement, 10 ng/ml epidermal 145 
growth factor, 90 µg/ml heparin, 1 µg/ml hydrocortisone (Supplement pack, Catalog Number 146 
C-39220, PromoCell), 100 U/mL penicillin streptomycin solution, and 50 ng/ml amphotericin 147 
B to yield Complete Medium in T-75 flask according to the manufacturer's instructions. 148 
Confluent HCAECs were washed with 15 ml of PBS, trypsinized, and replated in complete 149 
medium, as described below. Endothelial cell activation was measured in HCAECs between 150 
passages 4 and 7. HCAECs were seeded at a density of 1-2 x 104 cells/well in 96- well plate 151 
and cultured for 2-3 days until the cells reached 90-95% confluency. To determine the effect 152 
of LDL on IL-8 secretion, HCAECs grown in Complete Medium were washed, placed in 153 
serum-free medium and incubated with LDL (50 µg protein/ml) for 6 h. The amount of IL-8 154 
released into the media was measured by an IL-8 ELISA Kit (R & D Systems, Minneapolis, 155 
Minnesota, USA). 156 
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 157 
Culture of primary human monocyte-derived macrophages  158 
Human monocytes were isolated from buffy coats (Finnish Red Cross Blood Transfusion 159 
Center, Helsinki, Finland) by centrifugation in Ficoll-Paque gradient as described [31]. 160 
Washed cells were suspended in DMEM supplemented with 100 U/ml penicillin and 100 161 
µg/ml streptomycin, counted, and seeded on 24 well-plates (1.5 million cells per well). After 162 
1 h incubation, non-adherent cells were removed, and the medium was replaced with 163 
macrophage-SFM medium (Gibco) supplemented with 1% penicillin-streptomycin and 10 164 
ng/ml of granulocyte macrophage colony-stimulating factor (GM-CSF) (Biosite, San Diego, 165 
USA). The cells were cultured for 7 days in the presence of GM-CSF to allow them to 166 
differentiate into GM-CSF macrophages. The medium was then changed every 2 to 3 days 167 
throughout the culture period. 168 
 169 
Cholesterol efflux from macrophage foam cells 170 
The monocyte-derived macrophages were incubated in DMEM (pH 7.4) containing 25 µg/ml 171 
of [3H]CE-acetyl-LDL for 24 h to induce the formation of foam cells. To measure cholesterol 172 
efflux, macrophages were washed with PBS, and fresh media containing the various HDL (25 173 
µg protein/ml) were added. After incubation for 16 h, the media were collected, centrifuged 174 
at 300 g for 10 min to remove cellular debris, and the radioactivity in the supernatants was 175 
determined by liquid scintillation counting. Cells were solubilized with 0.2 M NaOH and 176 
analyzed for radioactivity. Cholesterol efflux was expressed as the percentage radioactivity in 177 
the medium relative to the sum of total radioactivity present in the medium and the cells. 178 
Cholesterol efflux to the incubation medium in the absence of HDL was considered as basal 179 
efflux and was subtracted from the efflux values obtained in the presence of HDL. In an 180 
initial experiment using THP-1 cells, a small increase in cholesterol efflux was observed in 181 
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the fatty fish group but not in other groups (data not shown). Therefore, the fatty fish group 182 
was selected to determine cholesterol efflux capacity using human primary macrophages, a 183 
relevantly physiological cell type. 184 
 185 
Analyses of SAA, apoE, serum lipids and lipoprotein subclasses 186 
Plasma apoE was assessed using ELISA Development Kit (catalog number 3712-1A-6; 187 
Mabtech, Nacka Strand, Sweden). SAA in serum was measured using Invitrogen SAA 188 
ELISA Kit (Cat nr. KHA0011, KHA0012 or KHA0011C; Thermo Fisher Scientific). 189 
Concentrations of serum total, LDL and HDL cholesterol were analyzed as previously 190 
described [25]. Serum concentrations of lipoprotein subclasses were measured using high-191 
throughput proton NMR spectroscopy, method has been described in detail previously [32].  192 
 193 
2.4 Statistical analyses 194 
IBM SPSS statistical software (v. 24, IBM Corp., Armonk, NY) was used for statistical 195 
analyses. The Kolmogorov-Smirnov test was used to test the normality of the variables and 196 
logarithmic transformation was performed for skewed variables. Non-parametric test was 197 
used if normality was not achieved with logarithmic transformation. For the comparison of 198 
baseline and endpoint values within the groups, paired samples t-test or Wilcoxon signed 199 
ranks test were used. The amount of cholesterol bound to aortic proteoglycans were 200 
normalized with LDL-, non-HDL cholesterol or apoB concentrations. Changes among the 201 
groups were tested with the analysis of variance (ANOVA) or Kruskall-Wallis -test. Analyses 202 
were performed using fold changes. Fold changes were calculated by dividing the endpoint 203 
values of the variable by their baseline values. Differences between genders in LDL 204 
aggregation were tested with Mann-Whitney’s U -test. Change in the cholesterol efflux 205 
capacity was tested with independent samples t-test. Associations between lipoprotein 206 
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subclasses and concentrations of apoE and SAA were tested using Spearman rank correlation. 207 
p < 0.05 was considered statistically significant. 208 
209 
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3. Results 210 
 211 
3.1. Characteristics of the participants and compliance 212 
Mean (± SD) age of the study subjects was 58.9 ± 6.5 years. Baseline characteristics of the 213 
study subjects are shown in Supplementary Table 1. Compliance with the study diets was 214 
good according to food records and consumption records regarding intakes of fish and CSO 215 
[25]. The proportion of ALA in plasma phospholipids increased in the CSO group (p < 0.001) 216 
and differed significantly from the other groups. Furthermore, the proportion of EPA 217 
increased (p < 0.001) in the fatty fish group as compared with the lean fish and control 218 
groups. The proportion of DHA increased in the fatty fish group (p < 0.001) as compared 219 
with the CSO and control groups. Similar changes were also observed in the proportions of 220 
these fatty acids in plasma cholesteryl esters, triglycerides and erythrocyte membranes [33].  221 
 222 
3.2 Binding of lipoproteins to proteoglycans 223 
Binding of lipoproteins to proteoglycans decreased in the CSO group compared with the fatty 224 
fish group in a non-normalized model (overall difference among the groups p=0.006, Fig. 225 
1A). After normalizing to serum LDL cholesterol, non-HDL cholesterol or apoB 226 
concentrations, the change was no longer statistically significant (p=0.771, p=0.625 and 227 
p=0.267, respectively), indicating that the level of apoB-containing lipoproteins in the 228 
circulation is the main driver of LDL retention to proteoglycans. 229 
   230 
3.3 LDL aggregation  231 
The susceptibility of LDL to aggregation has recently been shown to differ significantly 232 
among human donors and to be associated with cardiovascular deaths [8]. Here, we again 233 
found significant individual differences in LDL aggregation, but found no statistically 234 
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significant change in LDL aggregation among the groups (overall difference among the 235 
groups p=0.152, Fig. 1B) or between genders (p=0.505).  236 
 237 
3.4 Activation of endothelial cells 238 
A previous study has shown that modulation of LDL lipid composition influences the ability 239 
of LDL to induce secretion of IL-8 from endothelial cells [10]. We determined the IL-8 level 240 
upon treatment of human coronary artery endothelial cells with LDL (50 µl/ml) isolated from 241 
0-week and 12-week samples. We found that dietary intervention did not influence the ability 242 
of LDL to stimulate IL-8 release (Fig. 1C), indicating that diet intervention does not affect 243 
the pro-inflammatory properties of LDL particles as determined by IL-8 secretion. 244 
 245 
3.5 Cholesterol efflux capacity 246 
We examined whether diet intervention would modulate the ability of HDL particles to 247 
promote cholesterol efflux. To this end, we isolated HDL particles from plasma in the same 248 
subjects before and after 12 weeks of fatty fish intervention and determined their cholesterol 249 
efflux from human primary foam cells. As shown in Fig. 1D, fatty fish treatment after 12 250 
weeks did not significantly affect the cholesterol efflux capacity of HDL. 251 
 252 
3.6 Concentrations of apoE and SAA 253 
There were no statistically significant changes in plasma concentration of apoE among 254 
groups (fold changes for CSO group 1.05, fatty fish group 0.92, lean fish group 1.05 and 255 
control group 0.97, overall difference among the groups p=0.322). Serum concentration of 256 
SAA decreased in the CSO and lean fish groups compared with the control group (overall 257 
difference among the groups p=0.011, Fig. 2).  258 
 259 
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3.7 Correlations between lipoprotein subclasses, SAA and apoE  260 
Correlations between lipoprotein subclasses, SAA and apoE are shown in Supplementary 261 
Tables 2–4. We found weak correlations between SAA and HDL subclasses (r=0.245–0.416, 262 
p<0.05) and apoE and HDL subclasses (r=0.223–0.306, p<0.05). HDL3 also correlated with 263 
LDL subclasses (r=0.383–0.629, p<0.01). 264 
 265 
 266 
4. Discussion 267 
 268 
In this study, we investigated the effect of fish and CSO intakes on binding of lipoproteins to 269 
proteoglycans, LDL aggregation, cholesterol efflux capacity and activation of endothelial 270 
cells. This is the first dietary intervention study to investigate all these lipoprotein functions 271 
in humans. We showed that intake of 30 ml (27 g) of CSO rich in ALA decreases the binding 272 
of lipoproteins to aortic proteoglycans compared with the fatty fish group. Previously, Jones 273 
et al. [34] found that corn/safflower oil and high-oleic canola oil decreased slightly the 274 
binding of LDL to biglycan. In the present study, we used whole plasma samples instead of 275 
isolated LDL particles. In this way, we were able to assess the effect of all plasma 276 
lipoproteins on cholesterol accumulation to proteoglycans. We have previously shown that 277 
intake of CSO decreases serum LDL cholesterol compared with the fatty fish and lean fish 278 
groups and IDL particle concentration compared with the lean fish group [25, 32]. Taken 279 
together, our findings show a clear relation between plasma apoB containing lipoprotein 280 
levels and the binding of lipoprotein-derived cholesterol to human aortic proteoglycans, a 281 
finding highlighting the importance of plasma lipoprotein levels in the accumulation of 282 
cholesterol within the arterial proteoglycans. 283 
 284 
The effect of a healthy Nordic diet has recently been shown to decrease LDL aggregation in 285 
most donors, the decrease associating with an increased consumption of poly- and 286 
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monounsaturated fatty acids [8]. Here, we found no change in the LDL aggregation among 287 
the groups, but it should be noted that the individual differences in LDL aggregation were 288 
large, as also reported earlier [8]. In that study, the diet-induced differences in LDL 289 
aggregation were shown to be due to differences in the surface lipids of LDL, so that a 290 
decrease in LDL-sphingomyelins was associated with decreased LDL aggregation. Neither 291 
CSO, fatty fish nor lean fish induced changes in the proportion of LDL-sphingomyelins in 292 
this study (unpublished data by Manninen et al.). Furthermore, it has been previously shown 293 
that plasma sphingomyelins are affected by genetic factors, which may partly explain the 294 
inter-individual variance found in LDL aggregation [35]. These differences in LDL 295 
aggregation related to individual differences and the potential underlying mechanisms require 296 
further investigation. 297 
 298 
Modulation of LDL lipid composition has previously been shown to induce the release of IL-299 
8 from endothelial cells [10, 36]. In these studies, changes in the LDL lipidome were induced 300 
enzymatically and increased content of free fatty acids and lysophosphatidylcholine was 301 
found to enhance IL-8 release. Instead, studies investigating dietary effects on LDL lipidome 302 
are scarce [8, 37], and to our knowledge, there are no previous studies investigating the 303 
effects of dietary intervention on inflammatory properties of LDL particles. Padro et al. [37] 304 
found that milk enriched with long-chain n-3 PUFA (0.375 g/250 ml milk) did not induce 305 
changes among lipid species of LDL. N-3 enriched milk, however, increased long-chain n-3 306 
PUFA content in cholesteryl esters, phosphatidylcholine and PC36:5/lysoPC16:0 ratio. 307 
Authors concluded that these changes may be associated with reduced inflammatory activity 308 
of LDL particles. Here, we found no change in the ability of LDL to release IL-8.  309 
 310 
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Previous research on the effects of n-3 fatty acids on cholesterol efflux has been controversial 311 
[38-41]. In experimental models, where macrophages have been directly exposed to EPA, 312 
cholesterol efflux capacity has been reduced [38, 39], whereas EPA-supplementation with a 313 
high dose (1.8 g/day) has been shown to enhance cholesterol efflux capacity of HDL from 314 
THP-1 macrophages in patients with coronary risk factors [40]. In the present study, the 315 
dietary intake of EPA in the fatty fish group was considerably lower: approximately 0.5 g/day 316 
[25]. Here, we found that intake of fatty fish had no effect on the cholesterol efflux capacity 317 
of HDL particles isolated from plasma. Furthermore, ALA-treatment has been found to 318 
increase cholesterol efflux capacity in foam cells by decreasing stearoyl CoA desaturase 1 319 
expression [41]. Thus, it appears that ALA-treatment may be able to influence the properties 320 
of macrophages rather than that of HDL particles. Overall, further studies are needed to 321 
elucidate the role of dietary n-3 PUFAs on cholesterol efflux capacity. 322 
 323 
SAA and apoE are known to contribute to atherosclerosis [14, 15]. SAA has been shown to 324 
have several atherogenic functions whereas apoE is best recognized for its anti-atherogenic 325 
properties. Both SAA and apoE are also potential mediators in the binding of HDL to 326 
proteoglycans [16, 42]. HDL2 has been found to inhibit the formation of the LDL-327 
proteoglycan complex more efficiently than HDL3. This is explained by the higher apoE 328 
content in large HDL particles compared with small HDL particles [43]. Here, we found no 329 
changes in plasma concentration of apoE in any of the groups, but there was a decrease in the 330 
serum concentration of SAA in the CSO and lean fish groups as compared with the control 331 
group. After excluding individuals with hs-CRP>10 mg/l at baseline or at the end of the study 332 
(n=3), there were no differences between the groups in the pairwise comparison (data not 333 
shown). Moreover, we found weak correlations between SAA and HDL subclasses and apoE 334 
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and HDL subclasses. HDL3 also correlated with LDL subclasses, which may be an indication 335 
of dyslipidemic profile including small HDL particles [44].  336 
 337 
The strengths of the current study include a randomized controlled study design and good 338 
compliance with study diets, as previously reported [25]. However, there are also some 339 
limitations to consider. Power calculations were based on differences in DHA in plasma 340 
phospholipids, and it is likely that there was not enough power to see all changes in these 341 
secondary outcome variables. Baseline omega-3 index of subjects was relatively high (> 8 % 342 
for all groups) [33], which may have attenuated the effects. Furthermore, subjects in this 343 
study were overweight and had impaired glucose metabolism. Therefore, the results of this 344 
study may not apply to individuals with normal body weight and glucose metabolism. 345 
 346 
In conclusion, intake of CSO, fatty fish or lean fish has no effect on LDL aggregation or 347 
activation of endothelial cells, and fatty fish intake has no effect on cholesterol efflux 348 
capacity in subjects with impaired glucose metabolism. Intake of CSO, however, decreases 349 
the binding of lipoproteins to aortic proteoglycans by decreasing serum apoB-containing 350 
lipoprotein concentrations. This finding highlights the importance of plasma lipoprotein 351 
levels in the accumulation of cholesterol within the arterial wall.   352 
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The study is registered in Clinicaltrials.gov (NCT01768429). 
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Figure 1. (A) Changes in the binding of lipoproteins to proteoglycans (n=79), (B) LDL aggregation 
(n=79), (C) activation of endothelial cells (n=16–19/group) and (D) cholesterol efflux capacity in the 
fatty fish group (n=16). Changes among groups in the binding of lipoproteins to proteoglycans, LDL 
aggregation and IL-8 were tested using Kruskall-Wallis test or analysis of variance followed by 
Bonferroni’s post hoc tests. The p-value in the box represents the overall difference among groups. 
Change in cholesterol efflux capacity in the fatty fish group was tested with independent samples t-
test. CSO, Camelina sativa oil.    
 
 
 
Figure 2. Changes in the concentration of SAA.  
Changes within groups were tested with Mann-Whitney’s U-test and changes among groups were 
tested using Kruskall-Wallis test. The p-value in the box represents the overall difference among the 
groups. CSO, Camelina sativa oil; SAA, serum amyloid A.   
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Highlights 
• Camelina oil intake decreases the binding of lipoproteins to aortic proteoglycans 
• Intakes of camelina oil or fish have no effect on LDL aggregation 
• Intake of fatty fish has no effect on cholesterol efflux capacity of HDL 
